Tetsuya Takada is a seasoned senior-level executive with over 25 years of progressive experience in the life sciences industry. Takada has a track record of success in new market penetration, product divestitures, and strategic alliance building. He is the founder and President of TIPharms & Company, Co., Ltd., a pharmaceutical consultancy specializing in R&D planning, outsourcing, technology transfers, alliance, licensing, and development of marketing solutions. Takada's notable achievements include successfully negotiating and closing an $80 million product divestiture deal for Pfizer Japan (formerly Wyeth) and overseeing product licensing, strategic alliance building, APIs, and regulatory affairs as the Head of the Regional Office (Japan) at Takeda (formerly Nycomed). Takada's expertise in developing market-entry strategies for Japan has helped several global pharmaceutical companies penetrate the Japanese market successfully.

Takada has worked with several organizations such as Ernst & Young, Pfizer Japan Inc., and many more; progressing through positions of increased authority. As a leader, Takada has led large, multi-skilled teams and enabled knowledge transfer among team members while fostering relationships with other business units to ensure operations' efficiency.

Tetsuya Takada holds an MBA from Nihon University, Graduate School of Business, and a B.Pharm from Tokushima Bunri University.